Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab…
- Trial name
- NCT00195676
- Testing
- adalimumab
- Where
- 104 sites in United States, Austria and 8 more
- Volunteers
- 1,469 people
- Sponsor
- Abbott
Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
- Trial name
- NCT07234591
- Testing
- Tyk2 inhibitor
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Usynova Pharmaceuticals Ltd.
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis, Overweight or Obesity
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1…
- Trial name
- NCT06857942
- Testing
- Tirzepatide
- Where
- 38 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Psoriasis
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
efficacy study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206387
- Testing
- Desoximetasone Spray 0.25%
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT03849404
- Testing
- Adalimumab
- Where
- 20 sites in Estonia, Georgia and 2 more
- Volunteers
- 413 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- VOYAGE 1 (NCT02207231)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 97 sites in United States, Australia and 8 more
- Volunteers
- 837 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Plaque Psoriasis
A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07765628
- Testing
- HS-20118
- Volunteers
- 120 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO).
- Trial name
- Serenity PsO (NCT05655299)
- Testing
- VTX958 Dose A, VTX958 Dose B, VTX958 Dose C
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 222 people
- Sponsor
- Ventyx Biosciences, Inc
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Moderate-to-severe Plaque Psoriasis
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
- Trial name
- NCT07879885
- Testing
- HS-20137
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hansoh BioMedical R&D Company
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed.
- Trial name
- NCT03431974
- Testing
- LD-Aminopterin oral capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Syntrix Biosystems, Inc.
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study.
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus
- Trial name
- NCT03858634
- Testing
- KPL-716
- Where
- 14 sites in United States
- Volunteers
- 58 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
This is a randomized, placebo-controlled, ascending single dose study of KHK4827 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous or intravenous administration of KHK4827 in healthy male…
- Trial name
- NCT01488201
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Moderate to Severe Plaque Psoriasis
An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III…
- Trial name
- BCD-085-7 (NCT03390101)
- Testing
- BCD-085 Q2W, BCD-085 Q4W
- Where
- Russia
- Volunteers
- 213 people
- Sponsor
- Biocad
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis, Psoriatic Arthritis
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Trial name
- ScreenX (NCT06382051)
- Testing
- PEST Screening group
- Where
- 30 sites in Canada
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.
- Trial name
- VESPUCCI (NCT04595409)
- Testing
- FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
- Where
- 16 sites in Estonia, Georgia and 2 more
- Volunteers
- 392 people
- Sponsor
- Bioeq GmbH